Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: Method development and differentiation of tracer delivery from receptor binding

Journal of Cerebral Blood Flow and Metabolism

Volumn 18, Issue 6, 1998, Pages 619-631

  Zubieta, Jon Kar ^a,b,c   Koeppe, Robert A ^a   Mulholland, G Keith ^a   Kuhl, David E ^a   Frey, Kirk A ^a,c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Human brain; Kinetic modeling; Muscarinic receptor; N methylpiperidyl benzilate; Positron emission tomography

Indexed keywords

1 METHYL 4 PIPERIDYL BENZILATE; MUSCARINIC RECEPTOR; TRACER;

ACCURACY; ADULT; ARTICLE; BRAIN PERFUSION; BRAIN REGION; COMPARTMENT MODEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; KINETICS; MALE; NORMAL HUMAN; OCCIPITAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECEPTOR BINDING; VISUAL STIMULATION;

EID: 0031799617     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004647-199806000-00004     Document Type: Article

References (32)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr AC19:716-723
2. Alpert NM, Eriksson L, Chang JY, Bergstrom M, Litton JE, Correia JA, Bohm C, Ackerman RH, Taveras JM (1984) Strategy for the measurement of regional cerebral blood flow using short-lived tracers and emission tomography. J Cereb Blood Flow Metab 4: 28-34
3. Bevington PR (1969) Data Reduction and Error Analysis for the Physical Sciences. New York, McGraw-Hill, pp 232-241
4. Buck A, Mulholland GK, Papadopoulos SM, Koeppe RA, Frey KA (1996) Kinetic evaluation of positron-emitting muscarinic receptor ligands employing direct intracarotid injection. J Cereb Blood Flow Metab 16:1280-1287
5. Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403
6. DeKosky ST, Harbaugh RE, Schmitt FA, Bakar RAE, Chui HC, Knopman DS, Reeder TM, Sherter AG, Senter HJ, Markesbery WR (1992) Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Ann Neurol 32:625-632
7. 11C-Methyl]benztropine. Synapse 5:213-223
8. Eckelman WC, Reba RC, Rzeszotarski WJ, Gibson RE, Hill T, Holman BL, Budinger TF, Conklin JJ, Eng R, Grisom MP (1984) External imaging of cerebral muscarinic acetylcholine receptors. Science 223:291-293
9. Enna SJ, Bennett JPJ, Bylund DB, Snyder SH, Bird ED, Iversen LL (1976) Alterations of brain neurotransmitter receptor binding in Huntington's chorea. Brain Res 116:531-537
10. Fahn S (1983) High dosage anticholinergic therapy in dystonia. Neurology 33:1255-1261
11. Frey KA, Hichwa RD, Ehrenkaufer RLE, Agranoff BW (1985) Quantitative in vivo receptor binding III: tracer kinetic modeling of muscarinic cholinergic receptor binding. Proc Natl Acad Sci USA 82:6711-6715
12. Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE (1991) Parametric in vivo imaging of benzodiazepine receptor distribution in hunman brain. Ann Neurol 30:663-672
13. 11C]scopolamine and positron emission tomography. J Cereb Blood Flow Metab 12:147-154
14. 15O blood flow studies in positron emission tomography. IEEE Trans Nucl Sci NS33:546-549
15. Janowski DS, El-Yousef MK, Davis JM, Sekerke HJ (1972) A cholinergic-adrenergic hypothesis of mania and depression. Lancet 2: 632-635
16. 11C]Tropanyl benzilate binding to muscarinic cholinergic receptors: Methodology and kinetic modeling alternatives. J Cereb Blood Flow Metab 14:85-99
17. 11C]N-methyl-4-piperidyl benzylate binding to muscarinic cholinergic receptors. J Nucl Med 33:882
18. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735-744
19. Koeppe RA, Hutchins GD, Rothley JM, Hichwa RD (1987) Examination of assumptions for local cerebral blood flow studies in PET. J Nucl Med 28:1695-1703
20. 11C]tropanyl benzilate. J Cereb Blood Flow Metab 16:303-310
21. 3H]pirenzepine. J Neurochem 46:274-279
22. Mash DC, Flynn DD, Potter LT (1985) Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117
23. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227
24. 123I]-4-iodolevetimide. J Cereb Blood Flow Metab 12:562-570
25. Mulholland GK, Jewett DW, Otto CA, Kilbourn MR, Sherman PS, Kuhl DE (1988) Synthesis and regional brain distribution of [C-11]N-methyl-4-piperidyl benzylate ([C-11]NMPB) in the rat. J Nucl Med 29:768
26. Ruberg M, Ploska A, Javoy-Agid F, Agid Y (1982) Muscarinic binding and choline acetyltransferase activity in parkinsonian subjects with reference to dementia. Brain Res 232:129-139
27. 125I]iodobenzilate transport and specific binding to muscarinic acetylcholine receptor in rat brain in vivo: implications for human studies. J Cereb Blood Flow Metab 10:781-807
28. Sims NR. Bowen DM, Allen SJ, Smith CC, Neary D, Thomas DJ, Davison AN (1983) Presynaptic cholinergic degeneration in patients with dementia. J Neurochem 40:503-509
29. Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y (1993) Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett 149:225-228
30. Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y (1994) An acute effect of triazolam on muscarinic cholinergic receptor binding in the human brain measured by positron emission tomography. Psychopharmacology 113:311-317
31. Tandon R, Greden JF (1989) Cholinergic hyperactivity and negative schizophrenic symptoms: a model of dopaminergic/cholinergic interactions in schizophrenia. Arch Gen Psychiatry 46:745-753
32. Wastek GJ, Yamamura HI (1978) Biochemical characterization of the muscarinic cholinergic receptor in human brain: Alterations in Huntington's disease. Mol Pharmacol 14:768-780